-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Gout is an arthropathy that causes acid crystals to be deposited in joints due to the disorder of uric acid metabolism in the body.
It has the characteristics of multiple complications, long course of disease, and severe attacks
.
Data shows that the number of patients with hyperuricemia in China has reached 170 million, of which more than 80 million are gout patients, which are increasing rapidly at a growth rate of 9.
7%.
The number of gout patients in 2020 is about 100 million
.
In the face of a large patient population, the sales scale of anti-gout preparations has risen rapidly.
In 2017, the terminal sales of public medical institutions in China were close to 900 million yuan, and by 2018 it directly soared to 1.
64 billion yuan, a growth rate of 83.
55%
.
Recently, the State Food and Drug Administration released information about drug approval documents pending receipt on November 19, 2021, including febuxostat tablets from Shandong Lang Nuo Pharmaceutical and febuxostat tablets from two pharmaceutical companies in Chongqing Shenghuaxi Pharmaceutical on the same day Overrated
.
In 2020, the sales of this product in physical pharmacies in Chinese cities will exceed 500 million yuan
.
According to relevant national policies, the quality and efficacy of drugs that have passed the consistency evaluation are equivalent to those of the original research drugs.
Appropriate support should be provided in terms of medical insurance payment.
Medical institutions should give priority to procurement and give priority to clinical selection
.
At the same time, under the influence of a series of medical reform policies such as mass procurement, passing consistency evaluation has also become an important condition before drugs participate in centralized procurement
.
Data show that febuxostat is a uric acid-lowering drug that reduces serum uric acid concentration by inhibiting uric acid synthesis and is suitable for long-term treatment of hyperuricemia in patients with gout
.
The product was developed by Japan's Teijin, and is currently on the market in more than 70 countries and regions including the United States, Europe, and Japan
.
In September 2018, the original research product was approved for import by the State Food and Drug Administration
.
Prior to this, domestically produced febuxostat has been approved for listing, involving companies including Zhu Yangxin, Wanbang, and Hengrui.
In 2018, the competition of these three pharmaceutical companies has been evenly matched
.
Febuxostat is a category B species in the National Medical Insurance List
.
Due to the clear effect of lowering uric acid and higher safety, febuxostat has a considerable sales volume in the domestic market
.
According to data from Meinenet, in 2018, the terminal sales of this product in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as China public medical institutions) have exceeded 1 billion yuan, and it is in China's public medical institutions.
The terminal anti-gout preparation market occupies a market share of nearly 67%
.
However, in 2020, the sales of this product will exceed 500 million yuan, and it is expected to decline in 2021.
Among them, Jiangsu Wanbang Biochemical and Pharmaceutical Group's market share accounts for more than half of the market
.
This is mainly related to the implementation of the centralized procurement policy
.
Febuxostat has entered the third batch of national centralized drug procurement catalogs.
The manufacturers involved include Jiangsu Wanbang (40mg, 16 tablets, winning price of 16.
48 yuan), Jiangsu Hengrui (40mg, 10 tablets, winning price of 15.
16 yuan) and Hangzhou Zhuyangxin Pharmaceutical (40mg, 12 tablets, the winning bid is 19.
79 yuan)
.
Although there are certain differences in the price of febuxostat in different bid-winning regions, overall, the price of the drug has fallen sharply, which is one of the reasons for the decrease in sales of the product in the short term
.
Up to now, there are 10 manufacturers of febuxostat tablets.
Judging from the review situation, 9 companies including Jiangsu Wanbang Biochemical and Pharmaceutical Group and Jiangsu Hengrui Medicine have all been reviewed
.
Among them, Jiangsu Wanbang Biochemical, a subsidiary of Fosun Pharma, was the leader of the evaluation, followed by Hengrui Medicine
.
In addition, nine companies including Chengdu Better Pharmaceuticals, Qingdao Baiyang Pharmaceuticals, and Zhejiang Asia-Pacific Pharmaceuticals submitted listing applications and are under review and approval
.
It is foreseeable that competition in the market for febuxostat tablets will become more intense in the future
.
It has the characteristics of multiple complications, long course of disease, and severe attacks
.
Data shows that the number of patients with hyperuricemia in China has reached 170 million, of which more than 80 million are gout patients, which are increasing rapidly at a growth rate of 9.
7%.
The number of gout patients in 2020 is about 100 million
.
In the face of a large patient population, the sales scale of anti-gout preparations has risen rapidly.
In 2017, the terminal sales of public medical institutions in China were close to 900 million yuan, and by 2018 it directly soared to 1.
64 billion yuan, a growth rate of 83.
55%
.
Recently, the State Food and Drug Administration released information about drug approval documents pending receipt on November 19, 2021, including febuxostat tablets from Shandong Lang Nuo Pharmaceutical and febuxostat tablets from two pharmaceutical companies in Chongqing Shenghuaxi Pharmaceutical on the same day Overrated
.
In 2020, the sales of this product in physical pharmacies in Chinese cities will exceed 500 million yuan
.
According to relevant national policies, the quality and efficacy of drugs that have passed the consistency evaluation are equivalent to those of the original research drugs.
Appropriate support should be provided in terms of medical insurance payment.
Medical institutions should give priority to procurement and give priority to clinical selection
.
At the same time, under the influence of a series of medical reform policies such as mass procurement, passing consistency evaluation has also become an important condition before drugs participate in centralized procurement
.
Data show that febuxostat is a uric acid-lowering drug that reduces serum uric acid concentration by inhibiting uric acid synthesis and is suitable for long-term treatment of hyperuricemia in patients with gout
.
The product was developed by Japan's Teijin, and is currently on the market in more than 70 countries and regions including the United States, Europe, and Japan
.
In September 2018, the original research product was approved for import by the State Food and Drug Administration
.
Prior to this, domestically produced febuxostat has been approved for listing, involving companies including Zhu Yangxin, Wanbang, and Hengrui.
In 2018, the competition of these three pharmaceutical companies has been evenly matched
.
Febuxostat is a category B species in the National Medical Insurance List
.
Due to the clear effect of lowering uric acid and higher safety, febuxostat has a considerable sales volume in the domestic market
.
According to data from Meinenet, in 2018, the terminal sales of this product in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as China public medical institutions) have exceeded 1 billion yuan, and it is in China's public medical institutions.
The terminal anti-gout preparation market occupies a market share of nearly 67%
.
However, in 2020, the sales of this product will exceed 500 million yuan, and it is expected to decline in 2021.
Among them, Jiangsu Wanbang Biochemical and Pharmaceutical Group's market share accounts for more than half of the market
.
This is mainly related to the implementation of the centralized procurement policy
.
Febuxostat has entered the third batch of national centralized drug procurement catalogs.
The manufacturers involved include Jiangsu Wanbang (40mg, 16 tablets, winning price of 16.
48 yuan), Jiangsu Hengrui (40mg, 10 tablets, winning price of 15.
16 yuan) and Hangzhou Zhuyangxin Pharmaceutical (40mg, 12 tablets, the winning bid is 19.
79 yuan)
.
Although there are certain differences in the price of febuxostat in different bid-winning regions, overall, the price of the drug has fallen sharply, which is one of the reasons for the decrease in sales of the product in the short term
.
Up to now, there are 10 manufacturers of febuxostat tablets.
Judging from the review situation, 9 companies including Jiangsu Wanbang Biochemical and Pharmaceutical Group and Jiangsu Hengrui Medicine have all been reviewed
.
Among them, Jiangsu Wanbang Biochemical, a subsidiary of Fosun Pharma, was the leader of the evaluation, followed by Hengrui Medicine
.
In addition, nine companies including Chengdu Better Pharmaceuticals, Qingdao Baiyang Pharmaceuticals, and Zhejiang Asia-Pacific Pharmaceuticals submitted listing applications and are under review and approval
.
It is foreseeable that competition in the market for febuxostat tablets will become more intense in the future
.
